All Articles

A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial. Read More ›

According to findings from a phase 3 trial presented at ASTRO 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life. Read More ›

Updated results from the ECHELON-1 clinical trial showed that the combination of brentuximab vedotin (Adcetris; BV) plus doxorubicin, vinblastine, and dacarbazine (AVD) as first-line therapy improves overall survival (OS) in patients with stage III-IV classical Hodgkin lymphoma compared with standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Read More ›

At the AVBCC 12th Annual Summit in 2022, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. Read More ›

According to published results from a phase 3, prospective, multicenter, randomized clinical trial, the addition of the CD-30–targeted antibody–drug conjugate brentuximab vedotin (Adcetris) to standard chemotherapy can reduce the risk for relapse in this population of patients while providing a better tolerability profile. Read More ›

Standardizing biosimilar adoption in oncology through the electronic health record can improve biosimilar utilization and reduce health system costs. Read More ›

Care management services are designed to engage patients as active partners in their healthcare so they can effectively manage their complex medical conditions. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with lung cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›

We review the latest clinical evidence from the phase 3 ICARIA-MM and IKEMA studies of isatuximab, an anti-CD38 mAb, in patients with RRMM. In addition, the cost implications of MM management and evolving approaches for mitigating the cost burden without compromising clinical outcomes for patients with MM are discussed. Read More ›

The ICARIA-MM and IKEMA-MM phase 3 trials have been pivotal in identifying Isa’s high efficacy and favorable tolerability profile as a notable therapy in the role of RRMM management. Recently, there have been additional updates illustrating the unique effects of Isa. This article focuses on these updates and how they may inform the role of Isa in the treatment of MM. Read More ›